Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMVT-1402 in Adult Graves' Disease (Japan, Phase 2b)
jRCT2031260059Phase 2Recruiting
- Sponsor
- Immunovant, Inc.
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of IMVT-1402 in Graves' disease (3 arms), sponsored by Immunovant, Inc. Primary endpoint: Percentage of participants who are euthyroid and off ATD at Week 26 (Dose 1). Started Apr 2026; status: recruiting.
02
Drugs
IMVT-1402
03
Conditions
Graves' disease
Beyond the preview
Go deeper on jRCT2031260059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260059.